DEFM14A: Avadel Shareholders to Vote on Alkermes Acquisition

Avadel Pharmaceuticals shareholders are invited to vote on Alkermes' proposed acquisition for $21.00 cash plus a $1.50 CVR per share, valuing the company at up to $2.37 billion.

Summary

• Alkermes plc will acquire Avadel Pharmaceuticals plc through a scheme of arrangement under Irish law.
• Avadel shareholders will receive $21.00 in cash per share and one non-transferable Contingent Value Right (CVR) for a potential additional $1.50 per share, totaling up to $22.50 per share.
• The total potential transaction equity value is approximately $2.37 billion, assuming the CVR payment is made.
• The CVR payment is contingent upon final FDA approval of LUMRYZ for idiopathic hypersomnia (IH) in adults by December 31, 2028, and the dismissal of specified Jazz Pharmaceuticals claims. The Jazz claims dismissal occurred on October 27, 2025.
• Avadel's Board of Directors unanimously recommends that shareholders vote FOR all proposals related to the transaction.
• Two special shareholder meetings (Scheme Meeting and Extraordinary General Meeting) are scheduled for January 12, 2026, to approve the Scheme and related resolutions.
• The transaction is expected to be completed in the first quarter of 2026.
• Avadel equity awards, including options, restricted stock units, and restricted stock awards, will be converted into cash and CVRs based on specific terms outlined in the Transaction Agreement.
• Alkermes estimates needing approximately $2.43 billion to fund the cash consideration and transaction costs, to be sourced from cash on hand and $1.51 billion in secured bridge financing.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to Avadel's historical trading prices, with a large cash component providing immediate value and a CVR offering additional upside. The competitive bidding process and the Avadel Board's unanimous recommendation, supported by financial advisors, indicate a favorable outcome for shareholders. The 'hell or high water' clause for antitrust and the pre-satisfied legal milestone for the CVR further de-risk the transaction for Avadel shareholders.

Positives

• The Scheme Consideration (assuming the CVR Milestone Payment is made) represents a premium of approximately 55% to Avadel's weighted average trading price over the three months prior to the original transaction announcement (October 21, 2025) and a 26% premium to the closing price on October 21, 2025.
• The consideration primarily consists of $21.00 per share in upfront cash, providing immediate liquidity and certainty of value to Avadel shareholders.
• The CVR offers an opportunity for an additional $1.50 per share upon the achievement of a specified milestone (LUMRYZ FDA approval for IH), with the 'Legal Event' component of the milestone already satisfied.
• Alkermes has committed to using 'Commercially Reasonable Efforts' to achieve the CVR Milestone, and the transaction includes a 'hell or high water' standard for Alkermes' antitrust efforts, increasing closing certainty.
• Alkermes has secured fully committed financing of approximately $2.43 billion for the cash component of the acquisition.
• The Avadel Board unanimously approved the transaction and recommends it to shareholders, supported by fairness opinions from Morgan Stanley and Goldman Sachs.
• The End Date for the transaction has been extended from 12 to 15 months, providing additional time for completion.

Negatives

• Avadel shareholders will no longer participate in the future earnings or growth of Avadel as an independent entity, beyond any potential CVR payment.
• The CVR payment of $1.50 per share is contingent on future events and is not guaranteed; the minimum payment under each CVR is zero if the Milestone is not achieved by December 31, 2028.
• Avadel will incur significant transaction costs and expenses, regardless of whether the transaction is consummated.
• The pendency of the transaction may cause disruptions to Avadel's business operations and relationships with employees, vendors, and customers.
• There is a risk that the transaction may not be consummated, which could negatively impact Avadel's share price and market perception.
• Restrictions are placed on Avadel's business conduct prior to the completion of the transaction.
• Certain executive officers may be subject to an excise tax under Section 4999 of the U.S. Internal Revenue Code on payments received in connection with the change of control.
• Avadel may be required to reimburse Alkermes for documented expenses up to 1% of the aggregate cash consideration under certain termination circumstances.

Risks

• Failure to obtain the required Avadel Shareholder approval for the Scheme Meeting Resolution or the Required EGM Resolutions.
• Required regulatory approvals (e.g., HSR Act, Irish High Court) may not be obtained, be delayed, or be subject to unanticipated conditions (e.g., divestitures).
• Inability of the parties to satisfy other conditions to, and to complete, the Transaction in a timely manner or at all.
• The occurrence of any event, change, or circumstance that could give rise to the termination of the Transaction Agreement, including circumstances that would require payment by Avadel of a termination fee.
• Significant transaction costs, fees, expenses, and charges.
• Risk of litigation and/or regulatory actions related to the Transaction or unfavorable results from litigation and proceedings that could arise in the future.
• Disruption of management's attention from Avadel's ongoing business operations due to the pendency of the Transaction.
• The effect of the announcement of the Transaction on Avadel's business relationships, operating results, and business generally.
• The inherent uncertainty with financial or other forecasts or projections.
• The impact of the Transaction not being completed on Avadel and its business and shareholders.
• Uncertainties related to Avadel's, Alkermes', or their affiliates' ability to achieve the CVR Milestone.
• Avadel's ability to successfully commercialize LUMRYZ in the United States for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
• Avadel's ability to maintain and receive additional regulatory approvals for LUMRYZ in any other jurisdictions outside the U.S., and any related restrictions, limitations, and/or warnings in the label of LUMRYZ.
• Avadel's expectations regarding the rate and degree of market acceptance for LUMRYZ.
• Avadel's reliance on a single marketed product, LUMRYZ.
• Avadel's ability to seek, maintain and receive additional U.S. regulatory approvals as well as commercialize LUMRYZ for indications beyond narcolepsy, including IH.
• Avadel's dependence on a limited number of suppliers for the manufacturing of LUMRYZ and certain raw materials.
• Avadel's ability to finance operations on acceptable terms, either through capital raising, debt, equity, royalty-based financings, or strategic partnerships.
• Potential impacts of tariffs, inflation, and rising interest rates on Avadel's business and future operating results.
• Avadel's ability to hire and retain key members of its leadership team and other personnel.
• The potential impacts due to global political instability and conflicts, such as terrorism, civil unrest, war and natural disasters in foreign countries on Avadel's business, financial condition and results of operations.
• The potential impact of changes in political conditions or financial markets, including new or increased trade restrictions, tariffs, or policies, as well as disruptions in securities, credit, or capital markets in the U.S. or abroad.
• Competition existing today or that may arise in the future, including from other treatments for narcolepsy and IH.
• LUMRYZ and valiloxybate to treat idiopathic hypersomnia or any other indication may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval or limit their commercial success.
• Regulatory approval processes are lengthy, time consuming and inherently unpredictable.
• If LUMRYZ and valiloxybate do not gain market acceptance or if Avadel fails to accurately forecast demand or manage its supply chain and product inventories, its business will suffer.
• Potential legal and regulatory actions by competitors, including litigation or exclusivity strategies, could delay or materially affect anticipated product commercialization efforts.
• Avadel's commercial capabilities and infrastructure may not be adequate to successfully continue to commercialize LUMRYZ for narcolepsy or to successfully commercialize LUMRYZ for idiopathic hypersomnia or valiloxybate.

Future Outlook

The transaction is expected to close in the first quarter of 2026. Alkermes anticipates the acquisition will be immediately accretive and enhance its revenue growth profile and profitability. Alkermes plans to leverage Avadel's commercial infrastructure and rare disease experience to support the potential launch of its orexin 2 receptor agonist candidate, alixorexton, and advance clinical studies for LUMRYZ label expansion in idiopathic hypersomnia and valiloxybate development. Operational and administrative reorganization of Avadel is expected post-completion, including potential consolidation of business locations and central corporate functions.

Management Comments

• The Avadel Board unanimously determined that the Transaction Agreement and the transactions contemplated by the Transaction Agreement, including the Scheme, are in the best interests of Avadel and the Avadel Shareholders and that the terms of the Scheme are fair and reasonable.
• The Avadel Board unanimously recommends that you vote FOR all proposals.
• Jerad G. Seurer, General Counsel & Corporate Secretary, stated: 'On behalf of the Avadel Board, thank you for your consideration and continued support.'
• Alkermes believes there is a compelling strategic and financial rationale for undertaking the Transaction, which would position Alkermes and Avadel as a leader in sleep medicine.
• Alkermes recognizes the skills, knowledge and experience of Avadel's employees and is excited to work with them to further expand the commercial portfolio and development pipeline, and grow the value, of the Combined Group in the longer term.

Industry Context

Alkermes plc is a global biopharmaceutical company focused on neuroscience, with a portfolio of commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, and a pipeline in neurological disorders including narcolepsy and idiopathic hypersomnia (IH). Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines, with its commercial product LUMRYZ, the first and only once-at-bedtime oxybate for narcolepsy. This acquisition positions Alkermes as a key player in the commercial sleep medicine market, leveraging Avadel's established commercial infrastructure and rare disease experience to potentially support Alkermes' own orexin 2 receptor agonist candidate, alixorexton, and advance LUMRYZ for IH and valiloxybate development. The industry faces challenges from complex regulatory and political regimes, evolving pricing environments, and increasing scrutiny of pharmaceutical pricing.

Comparison to Industry Standards

• Morgan Stanley's analysis of comparable acquisition transactions (public biopharmaceutical targets between $1 billion and $10 billion in aggregate value, all-cash consideration since January 1, 2025) indicated a range of premia to the unaffected stock price of 27% to 79%. The Scheme Consideration (assuming CVR payment) represents a 40% premium to Avadel's unaffected stock price of $15.80 (October 20, 2025), falling within this range.
• The same analysis showed premia to the acquired company's 52-week high price ranging from 6% to 38%. The Scheme Consideration (assuming CVR payment) represents a 35% premium to Avadel's 52-week high price of $16.65 (Unaffected Date), which is at the higher end of this range.
• The 'hell or high water' standard for Alkermes' antitrust efforts obligations, as amended in the Transaction Agreement, is a strong commitment to obtaining regulatory approvals, which can be more favorable than typical industry standards and increases closing certainty.

Management Changes

Corporate Governance

Legal Proceedings

• The 'Legal Event' condition for the CVR, which involved the dismissal of specified claims with prejudice by the United States District Court for the District of Delaware pursuant to a Settlement and License Agreement with Jazz Pharmaceuticals, Inc., was satisfied on October 27, 2025.
• The Settlement Agreement with Jazz Pharmaceuticals, Inc. included a payment of $90 million to Avadel CNS Pharmaceuticals, LLC and a waiver of Jazz's right to receive royalties/damages on LUMRYZ sales through September 30, 2025.
• Avadel CNS Pharmaceuticals, LLC will pay royalties to Jazz: 3.85% of narcolepsy LUMRYZ net sales (from October 1, 2025) and 10% of IH LUMRYZ net sales (from March 1, 2028).
• The Settlement Agreement granted Avadel CNS a worldwide, non-exclusive, perpetual, irrevocable, non-terminable, non-transferrable royalty-bearing license to Jazz patents that could be asserted against LUMRYZ.
• Jazz agreed not to challenge the approval or approvability of LUMRYZ, and Avadel agreed not to market LUMRYZ in non-narcolepsy indications before March 1, 2028.
• Avadel CNS granted Jazz a royalty-free covenant not to sue Avadel CNS patents in connection with XYWAV and XYREM.
• There is a general risk of Transaction-related litigation.

Related Party Transactions

• No undisclosed related party transactions are reported; all transactions required to be disclosed under Item 404 of Regulation S-K have been disclosed in Avadel's SEC Documents filed prior to the date of the agreement.

Stakeholder Impact

• Shareholders: Will receive $21.00 cash per share and a CVR for a potential additional $1.50 per share, providing immediate liquidity and potential upside, but will no longer participate in Avadel's future growth as an independent entity.
• Employees: Alkermes will safeguard existing employment rights, including pension rights. Annual base salary/wage and target cash bonus opportunity will be no less favorable in aggregate for a period of one year post-Effective Time or until termination. Pension and welfare benefits will be no less favorable in aggregate than those of similarly situated Alkermes employees. Some operational and administrative reorganization is anticipated, potentially affecting central corporate and support functions. Transaction bonuses up to $1 million may be granted to employees (excluding executive officers).
• Executive Officers/Directors: Equity awards will be converted to cash and CVRs. Severance benefits upon qualifying termination, including enhanced benefits in connection with a change of control. 2025 annual bonuses will be paid at the greater of target or actual performance if completion occurs before normal payment date. Potential for excise tax under Section 4999 of the Code. Entitled to continued indemnification and insurance coverage. Directors intend to resign upon completion.
• Customers/Patients: The combined entity aims to further expand the commercial portfolio and development pipeline, supporting LUMRYZ and other candidates, which could potentially benefit patients.
• Suppliers/Creditors: Alkermes has committed financing, suggesting stability for creditors. Efforts will be made to preserve relationships with suppliers as part of business preservation.

Next Steps

• Avadel shareholders will vote on the Scheme and related resolutions at the Scheme Meeting and Extraordinary General Meeting on January 12, 2026.
• The Irish High Court hearing for Scheme sanction is anticipated in February 2026.
• The transaction is expected to be completed in the first quarter of 2026.
• Avadel Shares will be delisted from Nasdaq Global and deregistered under the Exchange Act following the completion of the transaction.
• Alkermes plans to integrate Avadel's business, evaluate consolidation of business locations, and combine operations to realize cost efficiencies.
• Alkermes will support the advancement of clinical studies for LUMRYZ label expansion in idiopathic hypersomnia and valiloxybate development.
• Alkermes intends to replace its bridge financing commitments or borrowings by accessing loan markets prior to or following the closing.

Key Dates

Recommendation

The acquisition offers a substantial premium (55% to 3-month VWAP, 26% to pre-announcement closing price) and a high degree of certainty with a large cash component ($21.00 per share). The additional $1.50 CVR provides attractive upside, especially since the 'Legal Event' condition has already been met. The 'hell or high water' clause for antitrust and the pre-satisfied legal milestone for the CVR further de-risk the transaction for Avadel shareholders. For investors seeking immediate liquidity and a strong premium, with a clear path to potential additional value, this is a highly favorable outcome.

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Scheme of Arrangement, LUMRYZ, Narcolepsy, Idiopathic Hypersomnia, Contingent Value Right, CVR, FDA Approval, Biopharmaceutical, Pharmaceutical Acquisition, Shareholder Vote, SEC Filing, Corporate Governance, Financial Analysis, Equity Awards, Takeover Rules